The effects of P-urogastrone/human epidermal growth factor (URO-EGF) on intestinal epithelial cell proliferation were studied in rats in which intestinal cell proliferation had been reduced to a steady state basal level, by maintaining the rats on total parenteral nutrition. The accumulation of arrested metaphases over a two hour time period was determined in a dose response study. Increasing doses of URO-EGF progressively raised the two hour collection of metaphases and intestinal weights. Intravenous infusion of URO-EGF was also effective in restoring cell proliferation when it was infused after the intestine had become hypoproliferative. ,-urogastrone/human epidermal growth factor administered through an intragastric cannulae thrice daily had no significant effect on intestinal weight or crypt cell production rate or metaphase collection. It is proposed that one of the in vivo actions of urogastrone-epidermal growth factor is the maintenance of gastrointestinal growth and that this occurs through a systemic rather than a luminal mechanism.
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corneal epithelium.5 j-urogastrone/human epidermal growth factor also stimulates the proliferation and maturation of the neonatal intestine,' where it also increases the activity of intestinal ornithine decarboxylase,' an enzyme associated with the initiation of cell proliferation."' The presence of URO-EGF in a variety of body fluids, including saliva, plasma' and milk," its production by the salivary and Brunners glands,'2 the reports of a trophic action of saliva on the intestine,'2'3 the demonstration of URO-EGF receptors in intestinal epithelial cells,'4'5 and the reported cytoprotective effects on the duodenal mucosa"' all suggest that it has a role in the control of gastrointestinal homeostasis other than its ability to inhibit gastric acid secretion. '7 It has been reported that the injection of URO-EGF into rodents increases the incorporation of tritiated thymidine into DNA throughout the gastrointestinal tract,'819 only in the stomach2' or only in starved animals.222 It has also been reported that URO-EGF stimulates gastrointestinal growth in undernourished young rats. 23 A study of the short term effects of URO-EGF administration using the more robust242" stathmokinetic method,26 showed a trophic effect which was only observed in some of the intestinal sites studied and depended on the time after injection; however, this study used starved rodents which were not in a steady state of cell proliferation.
A more suitable model of the hypoplastic intestine exists in the rat maintained by isocaloric total parenteral nutrition (TPN),27 which is generally agreed to be the pertinent system for the study of effects of humoral factors on the intestine,28 as the intestine of the TPN rat is in a steady state, basal level of proliferation, with the direct and indirect effects of food (luminal nutrition)' being abolished, and the effects of endogenous secretions considerably reduced.
We have used such a model to show that relatively low doses of URO-EGF, which should not alter acid secretion, can significantly increase intestinal epithelial cell proliferation in TPN rats.0 This model was used to further investigate the effects of recombinant URO-EGF on cell proliferation in the gastrointestinal tract. The first experiment reported in this paper investigated the effects of intravenous URO-EGF in a dose response study. The second experiment investigated the time course of the effects of URO-EGF when given after the intestine had atrophied (intervention). The effects of the intragastric administration of URO-EGF on crypt cell production rate and metaphase collection were also investigated.
Methods

ANIMALS
Male 200 g Wistar rats (Olac Ltd, Blackthorn, Oxon, UK) were housed individually in wire bottomed Perspex cages. The rats had constant access to tap water and were subjected to a 14 hour light, 10 hour dark schedule. The rats were maintained on the respective treatments for 10 days, unless stated otherwise. Before the experiments the rats were maintained on a pelleted diet, Labshure PRD (Labshure Ltd, Poole, Dorset, UK).
P-UROGASTRONE/HUMAN EPIDERMAL GROWTH
FACTOR
The URO-EGF was recombinant polypeptide (supplied by ICI and G D Searle) derived from the expression of a synthetic gene in E coli3' and purified to >97% by tryptic digestion and purification as judged by amino acid analysis, HPLC in two systems and by acrylamide gel electrophoresis.3' It had the same amino acid sequence as natural human URO-EGF.32 The biological activity of the cloned URO-EGF was identical to that of natural URO-EGF purified from human urine in its ability to inhibit gastric acid secretion, its mitogenicity to cultured fibroblasts,32 its binding to EGF receptors, and it had identical radioimmunoassay standard curves to URO-EGF purified from human urine.33
In the dose response study the rats were maintained by total parenteral nutrition (TPN), and URO-EGF was infused with the diet to give a daily intake of 0, 3, 15, 60 and 300 ig/rat/day (15 [tg/rat/ day was the dose used in our earlier study" and all except the highest dose should be within the range quoted for rodent EGF.3 In the intragastric infusion studies URO-EGF was given at 8 00 h, 1600 h and 2400 h. The daily doses used were 15, 150, and 300 mg/rat/day. The cannulae, silastic tubing and the swivel joints were sterilised by autoclaving. The other tubing, inlet manifold (made of plastic 3-way Luer fitting taps) and connectors were sterilised by pumping detergent Hypochlorite solution through the assembled system, followed by a thorough rinse with sterile saline.
TPN DIET
The TPN diet was made up in sterile conditions in three litre infusion bags. The diet was kept in a fridge at 4°C and was pumped into the rats through vinyl tubing. One litre of the diet contained the following: 714 ml Vamin glucose, 92 ml Intralipid 20% (Kabivitrum Ltd, Riverside Way, Uxbridge), 140 ml dextrose 50%, 9 ml Vitlipid infant (Kabivitrum), 1 vial Solvito (Kabivitrum), 20 ml Addiphos (Kabivitrum), 12-8 ml 10% calcium gluconate, 3-4 ml 50% magnesium sulphate, and 8*7 ml 23-4% sodium chloride. Each rat was infused with 60 ml/day giving 1-8 g N, as purified amino acids, which is equivalent to 11 5 g of first class protein; 6-0 g lipid; 8 5 g glucose and 1047 kJ (250 kcal) per kg of rat per day.
Urine was tested regularly for protein, glucose, ketone, bilirubin, blood, urobilinogen, specific gravity and pH with Multistix-SG (Ames Reagent Strips, Miles Laboratories Ltd, Slough, UK) and no signs of metabolic imbalance were seen in any group of rats, except those on the highest intravenous dose of URO-EGF which looked sick and had traces of blood and glucose in their urine.
AUTOPSY PROCEDURE
The rats were given 1 mg/kg vincristine sulphate (Eli Lilly, Basingstoke, UK) intravenously, and killed by injection of 12 mg of pentobarbitone and exsanguination. The rats were weighed and the net weight of gut tissues determined. The stomach, small intestine, caecum and colon were removed, rinsed, blotted, and weighed. The Figure 3 . There was a gradual increase in metaphases over the first 24 hours, becoming apparent 12 hours after the administration of URO-EGF in the stomach and small intestine; however there was no evidence of increased cell proliferation in the colon until 18 hours after the administration of URO-EGF. The rate of increase in arrested metaphases then levelled out after 24- Luminal administration of higher doses of URO-EGF also had no effect on either the weight of the intestine or the two hour metaphase accumulation (Table 4) . Table 3 Effects ofl5pglratlday ofurogastrone administered intragastrically on the crypt cell production rates ofthe different sites in the gastrointestinal tract The rats were on their respective treatments for 10 days. The crypt cell production rate is expressed as cells produced per crypt per hour. There were seven animals per group.
Table4 Effects of150 pglratlday urogastrone and 300 pglratlday urogastrone on the two hour collection of The treatments lasted for 10 days. There were four animals in the control group, five in the 150 ,tg/rat/day group and four in the 3tX) Ftg rat/day group. The results of the present study show that URO-EGF will stimulate intestinal epithelial cell proliferation and growth in TPN rats in all sites of the gastrointestinal tract in a dose dependent manner, with the most marked effects being observed in the stomach and colon. We have previously shown that a relatively low dose, which should not inhibit acid secretion, significantly increased crypt cell production throughout the intestine, with the CCPR's of the stomach and colon increasing to the levels observed in orally fed rats.3" P-urogastrone/human epidermal growth factor was also effective in stimulating proliferation once hypoplasia had become established. The time course of events after this 'intervention' are described. The intragastric infusion of URO-EGF had no effect on intestinal weight or CCPR at the same dose that had significant effects throughout the intestine when given intravenously, nor did it have any effect on intestinal weight or metaphase collection at higher doses. Tissue wet weight is only a crude measure of intestinal hyperplasia, but when it is combined with increased metaphase collection can confirm that these increases in proliferation are linked to hyperplasia. We have also shown that these weight changes are accompanied by similar, significant changes in villus height and crypt depth ( Table 2) .
The intestinal atrophy associated with TPN should occur within a few days2' and the similarity between the two hour metaphase accumulations after four days of TPN in the intervention study and after 10 days TPN in the other studies, and the high degree of comparability between the various (TPN) control groups substantiates this; thus the TPN control rats should have been in a 'steady state' of reduced intestinal proliferation. The rats maintained on TPN showed a slight gain in body weight despite the surgery, loss of digesta and gut tissue. 3-urogastrone/ human epidermal growth factor treated rats showed a greater weight gain which could be explained by the increase in gut weight. The rats dosed intragastrically all lost some weight but no significant differences between groups was noted.
The dose response studies showed that there was a log linear relationship between dose of URO-EGF and proliferation. The response of the different sites varied with the colon showing the most pronounced response increase. One could speculate that this reflects variations in receptor number among the cell populations,
The increase in proliferation in the intervention study was seen after 12 hours in the stomach and small intestine but only after 18 hours in the colon. Similar differences in the time course of proliferative increase have been observed in the intestine of starved mice after refeeding,3 which implied that the delay in colonic response was the consequence of the greater time taken for digesta to reach the colon; however, the present results suggest that this delay reflects some inherent difference between the colon and the stomach-small intestine. The time taken for a proliferative response is a function of the cell cycle time of the tissue involved,36 thus the present result could be a reflection of the longer cycle time of the colonocyte. 37 The exact shape of time course curves is obscured by the variability of the data. The increase in proliferation in some intestinal sites appeared to tail off. The proliferation in other sites did not appear to do so, and in some of these sites proliferation seemed to be increasing again at the end of the investigation.
The intragastric infusion of various doses of URO-EGF had no significant effect on intestinal weights, CCPR or two hour metaphase collection. This is in conflict with the results of Dembinski et al22 who reported a trophic response of the stomach and duodenum when 30 ,ug/kg/day of URO-EGF was given intragastrically to rats. Although URO-EGF is taken up by the digestive tract in the neonate and weanling rat,"8 recent evidence suggests that it is not absorbed in the adult gut."" It has also been reported that intragastric URO-EGF has a cytoprotective action in the damaged gastric mucosa'6; however, the intestine was not damaged in this study. intestine of parenterally fed rats. 
urogastrone-EGF is trophic to the Intravenous but not intragastric
